This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway
Journal of Translational Medicine Open Access 12 August 2023
Access options
References
Original article
Ho, P. et al. The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity. Preprint at bioRxiv https://doi.org/10.1101/2022.03.21.485049 (2022)
Related article
Quastel, M. Preprint Journal Club. PreprintClub https://www.preprintclub.com/2022-apr-ho (2022)
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Quastel, M., Dustin, M. The CD58–CD2 axis in cancer immune evasion. Nat Rev Immunol 22, 409 (2022). https://doi.org/10.1038/s41577-022-00738-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-022-00738-9
This article is cited by
-
CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway
Journal of Translational Medicine (2023)